Numbers Flashcards

1
Q

<p>PKU incidence</p>

A

<p>1:100,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

<p>PKU and risk congenital heart defect</p>

A

<p>7-10%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

<p>Fetal Phe levels </p>

A

<p>1.25-2.5x more than maternal</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

<p>Woman >40yo how many pregnancies unplanned?</p>

A

<p>20%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

<p>Percentage of TOP in women >40yo</p>

A

<p>28%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

<p>Background risk VTE in non-pregnant non-contraceptive users</p>

A

<p>2:10,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

<p>% normal population with anti phospholipid antibodies </p>

A

<p>1-2%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

<p>% of those with recurrent thrombosis with APS</p>

A

<p>20%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

<p>% of those with recurrent miscarriage with APS</p>

A

<p>15%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

<p>Risk of female carrier BRCA 1 developing breast cancer <70</p>

A

<p>60-80%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

<p>Risk of female carrier of BRaC-2 developing breast ca <70</p>

A

<p>45-85%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

<p>Incidence ectopic UK</p>

A

<p>11:1000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

<p>Incidence perforation in OP hysteroscopy</p>

A

<p>0.002-1.7%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

<p>Incidence of perforation in hysteroscopic surgery</p>

A

<p>1.6%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

<p>Perforation in ERPC for PPH</p>

A

<p>5%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

<p>Perforation for PMB Ix</p>

A

<p>0.2-2%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

<p>Perforation in TOP</p>

A

<p>0.4-0.5%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

<p>Cure rate GTD/GTN</p>

A

<p>98-100%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

<p>Incidence GTD</p>

A

<p>1:714 live births</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

<p>PCOS in reproductive age</p>

A

<p>10-18%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

<p>Metabolic syndrome in PCOS</p>

A

<p>33%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

<p>Sickle cell heterozygous (trait) in UK</p>

A

<p>240,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

<p>Sickle cell disease UK</p>

A

<p>12,500</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

<p>Lifetime prevalence of uterovaginal prolapse</p>

A

<p>30-50%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

<p>Per cent of women who have had surgery for UV prolapse by 80yo</p>

A

<p>12%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

<p>VBAC success overall</p>

A

<p>72-75%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

<p>VBAC + prev vaginal delivery success</p>

A

<p>85-90%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

<p>Success of VBAC + prev CS for fetal malpresentation </p>

A

<p>84%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

<p>Success of VBAC if prev CS fetal distress</p>

A

<p>73%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

<p>Success of VBAC + prev cs for Labour dystocia</p>

A

<p>64%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

<p>Background risk VTE women in 1 yr</p>

A

<p>2:10,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

<p>Risk VTE in CHC + ethinlyestradiol + levogernestrel/norgestimate/norethisterone</p>

A

<p>5-7:10,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

<p>Risk of VTE in etonogestrel (ring) or norelgestromin (patch)</p>

A

<p>6-12: 10,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

<p>Risk VTE with ethinylestradiol + gestodone/desogestrel/drosperinone</p>

A

<p>9-12:10,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

<p>Conception rate after UPA (within 120hrs)</p>

A

<p>1.3%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

<p>Conception rate after LNG</p>

A

<p>2.2%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

<p>Women who have gonorrhiea and chlamydia co-infection </p>

A

<p>40%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

<p>UV prolapse lifetime prevalence</p>

A

<p>30-50%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

<p>Vaginal vault prolapse recurrence after uterosacral ligament suspension</p>

A

<p>5-12%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

<p>Recurrence rate of vaginal vault prolapse after sacrocolpopexy</p>

A

<p>3-5%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

<p>Rate of increased UI after VH</p>

A

<p>60% over 60yo</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

<p>Dyspareunia after anterior repair</p>

A

<p>15%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

<p>Risks of sacrocolpopexy

- mesh erosion
- SBO
- ileus
- recurrence</p>

A

<p>10.5%
1.2%
0.3%
3-5%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

<p>Per cent of women in lifetime who will have surgery for ovarian mass</p>

A

<p>10%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

<p>Incidence of ovarian cyst in premenopausal being malignant</p>

A

<p>1:1000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

<p>Incidence of ovarian cyst being malignant in 50yo</p>

A

<p>3:1000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

<p>Per cent of TOA being malignant in postmenopausal</p>

A

<p>49%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q
<p>Per cent with chronic pelvic pain after 
1 episode
2 episodes 
3 episodes
Of PID/TOA</p>
A

<p>12%
30%
67%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

<p>Per cent of women under 40 affected by POI</p>

A

<p>1%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

<p>Most common cause of premature ovarian insufficiency</p>

A

<p>Idiopathic 90%

| Chromosomal, AI, infective and iatrogenic 10%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

<p>IVF - mild OHSS</p>

A

<p>33%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

<p>IVF - mod/severe OHSS</p>

A

<p>3-8%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

<p>Prevalence of POI</p>

A

<p>1:100</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

<p>Main cause of POI</p>

A

<p>90% idiopathic</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

<p>Sensitivity of amniocentesis for diagnosing fetal CMV?</p>

A

<p>60-70%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

<p>Percentage of clinically significant red cell autoantibodies in pregnancy</p>

A

<p>0.4%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

<p>Percentage of red cell autoantibodies in pregnancy</p>

A

<p>1.2%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

<p>Level of anti K to refer to fetal med</p>

A

<p>any</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

<p>Level of anti D to refer to fetal med</p>

A

<p>>4</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

<p>Level of anti C to refer to fetal med</p>

A

<p>>7.5</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

<p>Level of anti E to refer to fetal med</p>

A

<p>When anti C detected</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

<p>Aim of transfusion PCV for fetal anaemia</p>

A

<p>PCV 0.7-0.85</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

<p>Aim of transfusion PCV for neonatal anaemia </p>

A

<p>PCV 0.5-0.6</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

<p>Percentage of women with bipolar disorder, without family history, of developing postpartum pyschosis</p>

A

<p>1:4</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

<p>Percentage of women with bipolar disorder, with family history, of developing postpartum pyschosis</p>

A

<p>1:2</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

<p>Risk of congenital infection with recurrent CMV</p>

A

<p>1-2%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

<p>Risk of congenital infection with primary CMV</p>

A

<p>30-40%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

<p>What percentage of infants with congenital CMV infection are symptomatic?</p>

A

<p>10-15%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

<p>Maternal mortality in UK?</p>

A

<p>8.76 per 100,000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

<p>Percentage of twins in live births?</p>

A

<p>3%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

<p>Incidence of puerperal genital haematoma?

| Requiring surgical intervention?</p>

A

<p>1:700

| 1:1000</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

<p>Congenital malformations of women with epilepsy without AEDs</p>

A

<p>2.8%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

<p>Valproate and congenital malformations</p>

A

<p>10.7%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

<p>AED Polytherapy and congenital malformations</p>

A

<p>16%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

<p>Risk of congenital malformations if previously affected child </p>

A

<p>16.8%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

<p>Lamotrigine and congenital malformations</p>

A

<p>2%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
77
Q

<p>Carbamazepine and congenital malformations</p>

A

<p>3.4%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
78
Q

<p>Keppra and congenital malformations</p>

A

<p>0.7%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
79
Q

<p>Phenobarbital and congenital malformations</p>

A

<p>4.9%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
80
Q

<p>Phenytoin and congenital malformations</p>

A

<p>7.36%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
81
Q

<p>Risk of seizure in labour with epilepsy</p>

A

<p>1-4%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
82
Q

<p>Percentage of brachial plexus injury in shoulder dystocia</p>

A

<p>2.3-16%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
83
Q

<p>Maximum dose of lidocaine + adrenaline</p>

A

<p>7ml/kg</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
84
Q

<p>Risk of future PIH if previous PIH</p>

A

<p>16-47%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
85
Q

<p>Risk of PET if previous PIH</p>

A

<p>2-7%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
86
Q

<p>Risk of PIH if previous PET</p>

A

<p>13-53%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
87
Q

<p>Risk of PET if previous PET</p>

A

<p>16%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
88
Q

<p>Risk of PET if previous severe PET/HELLP/eclampsia led to birth <34/40</p>

A

<p>25%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
89
Q

<p>Risk of PET if previous eclampsia led to birth <28/40</p>

A

<p>55%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
90
Q

<p>Risk RDS at 37/40 ELCS</p>

A

<p>11%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
91
Q

<p>Risk RDS at 38/40 ELCS</p>

A

<p>8%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
92
Q

<p>Risk RDS at 39/40 ELCS</p>

A

<p>1.5%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
93
Q

<p>Steroids reduce RDS by what per cent?</p>

A

<p>44%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
94
Q

<p>Risk of miscarriage with amniocentesis</p>

A

<p>0.11%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
95
Q

<p>Risk of miscarriage with CVS</p>

A

<p>0.22%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
96
Q

<p>Percentage of inconclusive cffDNA tests</p>

A

<p>1.9-6%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
97
Q

<p>cffDNA sensitivity and specificity for T21</p>

A

<p>99.4%, 99.9%</p>

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
98
Q

<p>cffDNA sensitivity and specificity for T18</p>

A

<p>97.7%, 99.9%</p>

99
Q

<p>Female tubal sterilisation failure rate</p>

A

<p>0.85-1.85%</p>

100
Q

<p>Incidence of adnexal masses in pregnancy
The incidence of ovarian malignancy in pregnancy
</p>

A

<p>0.19–8.8%

| 1 in 1500–32 000 pregnancies</p>

101
Q

<p>Hyperreactio luteinalis - percentage of maternal virilisation?</p>

A

<p>14-25%</p>

102
Q

<p>Luteoma of pregnancy - percentage of maternal virilisation?</p>

A

<p>25-50%

| 50% of these have risk of fetal virilisation if female</p>

103
Q

<p>Risk of heterotopic pregnancy in assisted reproduction?</p>

A

<p>1-2%</p>

104
Q

<p>Risk of torsion of >6cm dermoid cyst in pregnancy</p>

A

<p>27%</p>

105
Q

<p>Percentage that malignant germ cell tumours account for in ovarian tumours in pregnancy?</p>

A

<p>38%</p>

106
Q

<p>Prevalence of acute appendicitis in pregnancy?</p>

A

<p>1:1500</p>

107
Q

<p>Percentage of adnexal masses that are simple ovarian cysts <5cm in pregnancy</p>

A

<p>76%</p>

108
Q

<p>Incidence of ovarian torsion in pregnancy</p>

A

<p>1-5:1000</p>

109
Q

<p>Risk of mid trimester losses after radical trachelectomy</p>

A

<p>7% vs 4% BG</p>

110
Q

<p>Risk of preterm births after trachelectomy</p>

A

<p>30%</p>

111
Q

<p>LBR after trachelectomy</p>

A

<p>62.8%</p>

112
Q

<p>Peripartum seizure risk in epilepsy</p>

A

<p>1-4%</p>

113
Q

<p>Percentage of women with vasomotor symptoms after menopause</p>

A

<p>70%</p>

114
Q

<p>Risk additional breast cancer cases if using HRT (E+P) for 5 years</p>

A

<p>6 extra per 1000

| (BG 22-48:1000 over 7.5yrs)</p>

115
Q

<p>Risk of radiation cystitis</p>

A

<p>26%</p>

116
Q

<p>Risk of bowel fistulae after radiotherapy for cervical ca.</p>

A

<p>8%</p>

117
Q

<p>Risk of bladder atony requiring ISC after radical hysterectomy</p>

A

<p>2-3%</p>

118
Q

<p>Risk of bowel obstruction after radiotherapy for cervical cancer</p>

A

<p>14.5%</p>

119
Q

<p>Dyspareunia post radiotherapy for cervical cancer</p>

A

<p>55%</p>

120
Q

<p>Recurrence of abruption after 1 previous</p>

A

<p>4%</p>

121
Q

<p>Recurrence after 2 previous abruptions</p>

A

<p>19-25%</p>

122
Q

<p>Risk of malignant potential in lichen sclerosis</p>

A

<p>5%</p>

123
Q

<p>Risk of malignant potential in lichen planus</p>

A

<p>3%</p>

124
Q

<p>5yr survival of Stage 1 cervical ca</p>

A

<p>80%</p>

125
Q

<p>5yr survival of Stage 2 cervical ca</p>

A

<p>50%</p>

126
Q

<p>5yr survival of Stage 3 cervical ca</p>

A

<p>20%</p>

127
Q

<p>5yr survival of Stage 2 cervical ca</p>

A

<p>7%</p>

128
Q

<p>Percentage of bilateral dysgerminomas</p>

A

<p>10%</p>

129
Q

<p>Percentage of raised CA125 in EOC</p>

A

<p>>80%</p>

130
Q

<p>Percentage of HMB due to submucosal fibroids</p>

A

<p>15%</p>

131
Q

<p>Pregnancy post endometrial ablation</p>

A

<p>0.7%</p>

132
Q

<p>Percentage of reoperation after endometrial ablation</p>

A

<p>20-27%</p>

133
Q

<p>Percentage of women having hysterectomy in 5 years after endometrial ablation</p>

A

<p>14-20%</p>

134
Q

<p>Percentage of women with cyclical bleeding post subtotal hysterectomy</p>

A

<p>5%</p>

135
Q

<p>Percentage of PCO in general population</p>

A

<p>20-33%</p>

136
Q

<p>Percentage of anovulatory infertility due to PCOS</p>

A

<p>80-90%</p>

137
Q

<p>Percentage of ovulation induction with clomiphene citrate</p>

A

<p>70-85%</p>

138
Q

<p>Percentage of patients pregnant after 6 cycles of clomiphene citrate</p>

A

<p>60-70%</p>

139
Q

<p>Risk of multiple pregnancy in clomiphene citrate ovulation induction</p>

A

<p>10%</p>

140
Q

<p>Risk of multiple pregnancy in gonadotrophin ovulation induction</p>

A

<p><5</p>

141
Q

<p>Percentage of endometriosis in reproductive age</p>

A

<p>6-10%</p>

142
Q

<p>Sensitivity and specificity of dyschezia and deep dyspareunia for deep infiltrating endometriosis</p>

A

<p>74.5%

| 68.7%</p>

143
Q

<p>Risk of premature ovarian failure in bilateral endometrioma cystectomies</p>

A

<p>2.4%</p>

144
Q

<p>Lifetime risk of colon cancer in Lynch syndrome</p>

A

<p>50-80%</p>

145
Q

<p>Lifetime risk of endometrial cancer in Lynch syndrome</p>

A

<p>40-60%</p>

146
Q

<p>Lifetime risk of ovarian cancer in Lynch syndrome</p>

A

<p>10-12%</p>

147
Q

<p>Risk of primary peritoneal malignancy in BRCA1/ BRCA2 with oophorectomy</p>

A

<p>1-6%</p>

148
Q

<p>5yr survival for ovarian cancer Stage 1</p>

A

<p>92%</p>

149
Q

<p>5yr survival for ovarian cancer Stage 2</p>

A

<p>55%</p>

150
Q

<p>5yr survival for ovarian cancer Stage 3</p>

A

<p>22%</p>

151
Q

<p>5yr survival for ovarian cancer Stage 4</p>

A

<p>6%</p>

152
Q

<p>5yr survival for ovarian cancer overall</p>

A

<p>43%</p>

153
Q

<p>5yr survival for endometrial cancer Stage 1</p>

A

<p>95%</p>

154
Q

<p>5yr survival for endometrial cancer Stage 2</p>

A

<p>77%</p>

155
Q

<p>5yr survival for endometrial cancer Stage 3</p>

A

<p>39%</p>

156
Q

<p>5yr survival for endometrial cancer Stage 4</p>

A

<p>14%</p>

157
Q

<p>5yr survival for endometrial cancer overall</p>

A

<p>84.4%</p>

158
Q

<p>Prevalence of cerebral palsy in <28/40</p>

A

<p>110:1000

| 1:10</p>

159
Q

<p>Prevalence of cerebral palsy between 28-31/40</p>

A

<p>43:1000</p>

160
Q

<p>Prevalence of cerebral palsy between 32-36/40</p>

A

<p>6.75:1000</p>

161
Q

<p>Prevalence of cerebral palsy in >36/40</p>

A

<p>1.35:1000</p>

162
Q

<p>Percentage of cerebral palsy due to PTB</p>

A

<p>35%</p>

163
Q

<p>Percentage of pregnant women with anaemia</p>

A

<p>38%</p>

164
Q

<p>Percentage of women with HMB and iron deficiency anaemia

| or with severe iron deficiency</p>

A

<p>27%

| 60%</p>

165
Q

<p>Percentage that an ectopic pregnancy with 1 previous CS is a scar pregnancy</p>

A

<p>6.1%</p>

166
Q

<p>Risk of recurrence of CS scar</p>

A

<p>3.25-5%</p>

167
Q

<p>5 year survival in recurrent cervical cancer</p>

A

<p>6-77%</p>

168
Q

<p>Pelvic exenteration mortality rate</p>

A

<p>Up to 14%</p>

169
Q

<p>Pelvic exenteration morbidity rate</p>

A

<p>33-75%

| Serious 50%</p>

170
Q

<p>5 year survival after pelvic exenteration</p>

A

<p>54%
87% of these survive 10yrs+
Higher success if >5yr disease free interval, R0 and no lymph node involvement</p>

171
Q

<p>Risk of recurrent pregnancy loss in prothrombin gene mutation</p>

A

<p>81%</p>

172
Q

<p>Percentage of maternal deaths with recognised mental health problem</p>

A

<p>16.8%</p>

173
Q

<p>Risk to baby with homebirth in nullips</p>

A

<p>4:1000</p>

174
Q

<p>Percentage of transfer of nullips from home to obs unit</p>

A

<p>45%</p>

175
Q

<p>Percentage of bowel injuries diagnosed post diagnostic laparoscopy</p>

A

<p>15%</p>

176
Q

<p>Percentage of bladder injuries diagnosed post diagnostic laparoscopy</p>

A

<p>50%</p>

177
Q

<p>Percentage of ureteric injuries diagnosed post diagnostic laparoscopy</p>

A

<p>70%</p>

178
Q

<p>Failure rate of lap. sterilisation</p>

A

<p>1:200</p>

179
Q

<p>Rate of adhesion at umbilicus after midline laparotomy</p>

A

<p>50%</p>

180
Q

<p>Rate of adhesion at umbilicus after low transverse incision</p>

A

<p>23%</p>

181
Q

<p>TOG - rate of bladder injuries in laparoscopy</p>

A

<p>0.02-8.3%</p>

182
Q

<p>% of fistula formation in laparoscopic bladder injury</p>

A

<p>5%</p>

183
Q

<p>% laparoscopic ureteric injury
% in LAVH
% in DIE</p>

A

<p>1-2%
9-11%
38%</p>

184
Q

<p>Laparoscopic ureteric injury

- lower 1/3
- middle 1/3
- upper 1/3</p>

A

<p>50%
30%
18%</p>

185
Q

<p>% unrecognised ureteric injuries resulting in a nephrectomy</p>

A

<p>25%</p>

186
Q

<p>% of neuro morbidity in DCDA if 1 twin death?</p>

A

<p>1%</p>

187
Q

<p>% of neuro morbidity in MCDA if 1 twin death</p>

A

<p>26%</p>

188
Q

<p>% of death in DCDA if 1 twin death</p>

A

<p>4%</p>

189
Q

<p>% of death in MCDA if 1 twin death</p>

A

<p>15%</p>

190
Q

<p>% of laparotomy conversion for laparoscopic hysterectomy</p>

A

<p>0.83-7%

0. 83% for subtotal
2. 79% for total</p>

191
Q

<p>% with adhesions after open gynae surgery</p>

A

<p>34.5%</p>

192
Q

<p>TOG: % of perforations by fitting an IUD

| % of these resulting in bowel injury</p>

A

<p>15%

| 3-7%</p>

193
Q

<p>Rate of hysterectomy following perforation from TOP</p>

A

<p>7:100,000</p>

194
Q

<p>% uterine perforations affecting anterior wall</p>

A

<p>40%</p>

195
Q

<p>% uterine perforations affecting cervix</p>

A

<p>36%</p>

196
Q

<p>% uterine perforations affecting right lateral wall</p>

A

<p>21%</p>

197
Q

<p>% uterine perforations by suction curette</p>

A

<p>51%</p>

198
Q

<p>% uterine perforations by Hegar</p>

A

<p>24%</p>

199
Q

<p>% uterine perforations by curette</p>

A

<p>16%</p>

200
Q

TVS sensitivity and specificity for Dx ectopic

A

87-99% sensitivity

94-99.9% specificity

201
Q

% of pseudosacs within uterine cavity in ectopic pregnancies

A

20%

202
Q

Incidence of CS scar pregnancies

A

1:2000

203
Q

% of interstitial in ectopic pregnancies

A

1-6.3%

204
Q

Incidence of cornual ectopics

A

1:67,000

205
Q

Ongoing pregnancy rate in salpingotomy

Repeat ectopics

A

60.7%

8%

206
Q

Ongoing pregnancy rate in salpingectomy

Repeat ectopics

A

56.2%

5%

207
Q

Rate of women needing further surgery after salpingotomy?

A

1:5

208
Q

Success rate of 1st dose of methotrexate in ectopic Mx

A

65-95%

209
Q

% needing 2nd dose of methotrexate for ectopic Mx

A

3-27% greentop

14% PassMRCOG

210
Q

Success rate of expectant Mx ectopics if HCG <1000

A

80-90%

211
Q

Success rate of expectant Mx ectopics if HCG <2000

A

60-67%

212
Q

% of recurrent ectopics

A

18.5%

213
Q

% of 2nd trimester miscarriages

A

1-2%

214
Q

% miscarriages 12-19yo

A

13%

215
Q

% miscarriages 20-24yo

A

11%

216
Q

% miscarriages in 25-29yo

A

12%

217
Q

% miscarriages in 30-34yo

A

15%

218
Q

% miscarriages in 35-39yo

A

25%

219
Q

% miscarriages in 40-44yo

A

51%

220
Q

% miscarriages in >45yo

A

93%

221
Q

% who miscarry after 3 consecutive miscarriages

A

40%

222
Q

% women with recurrent miscarriages and congenital uterine malformations

A

1.8-37.6%

223
Q

% women needing chemotherapy with complete molar pregnancy

A

15%

224
Q

% women needing chemotherapy with partial molar pregnancy

A

0.5%

225
Q

GTN incidence

A

1:50,000 after live birth

226
Q

Incidence GTD

A

1:714 live births

227
Q

GTN cure rate

A

98-100%

228
Q

% LBR in twin pregnancy with co-existent molar

A

25%

229
Q

% miscarriage in twin pregnancy with co-existent molar

A

40%

230
Q

% PTB in twin pregnancy with co-existent molar

A

36%

231
Q

GTN cure rate FIGO <6

A

almost 100%

232
Q

GTN cure rate FIGO >7

A

almost 95%

233
Q

% hyperemesis gravidarum

A

0.3-3.6%

234
Q

Hyperemesis gravidarum recurrence

A

15.2-81%

235
Q

% pregnancy loss in Wernicke’s encephalopathy

A

48%

236
Q

% women with OHSS managed as inpatients

A

0.3%

237
Q

% of cerebral palsy in 22-27/40

A

14.6%

238
Q

% of cerebral palsy in 28-31/40

A

6.2%

239
Q

% of cerebral palsy in 32-36/40

A

0.7%

240
Q

% of cerebral palsy in term

A

0.1%

241
Q

% fetal loss in simple appendicitis

A

1.5%

242
Q

% fetal loss in appendicitis with peritonitis

A

6%

243
Q

% fetal loss with perforated appendix

A

36%